Objective

To analyze long-term clinical and biomarker features of anti-contactin-1 (CNTN1) autoimmune nodopathy (AN).

Methods: Patients with anti-CNTN1+ autoimmune nodopathy detected in our laboratory from which clinical information was available were included. Clinical features and treatment response were retrospectively collected. Autoantibody, serum neurofilament light chain (sNfL), and serum CNTN1 levels (sCNTN1) were analyzed at baseline and follow up.

Results

A total of 31 patients were included. Patients presented with progressive sensory motor neuropathy (76.7%) with proximal (74.2%) and distal involvement (87.1%), ataxia (71.4%), and severe disability (median INCAT at nadir of 8). A total of 11 patients (35%) showed kidney involvement. Most patients (97%) received intravenous immunoglobulin, but only 1 achieved remission with intravenous immunoglobulin. A total of 22 patients (71%) received corticosteroids, and 3 of them (14%) did not need further treatments. Rituximab was effective in 21 of 22 patients (95.5%), with most of them (72%) receiving a single course. Four patients (12.9%) relapsed after a median follow up of 25 months after effective treatment (12-48 months). Anti-CNTN1 titers correlated with clinical scales at sampling and were negative after treatment in all patients, but 1 (20/21). sNfL levels were significantly higher and sCNTN1 significantly lower in anti-CNTN1+ patients than in healthy controls (sNfL: 135.9 pg/ml vs 7.48 pg/ml, sCNTN1: 25.03 pg/ml vs 22,186 pg/ml, p < 0.0001). Both sNfL and sCNTN1 returned to normal levels after successful treatment.

Interpretation

Patients with anti-CNTN1+ autoimmune nodopathy have a characteristic clinical profile. Clinical and immunological relapses are infrequent after successful treatment, suggesting that continuous treatment is unnecessary. Anti-CNTN1 antibodies, sNfL, and sCNTN1 levels are useful to monitor disease status in these patients. ANN NEUROL 2025;97:529-541.

1. Martín-Aguilar, L., Lleixà, C., & Pascual-Goñi, E. (2022). Autoimmune nodopathies, an emerging diagnostic category. Current Opinion in Neurology, 35(5), 579–585. https://doi.org/10.1097/WCO.0000000000001107
2. Uncini, A., & Vallat, J. M. (2018). Autoimmune nodo-paranodopathies of peripheral nerve: The concept is gaining ground. Journal of Neurology, Neurosurgery & Psychiatry, 89(6), 627–635. https://doi.org/10.1136/jnnp-2017-317192
3. Querol, L., Nogales-Gadea, G., Rojas-Garcia, R., et al. (2013). Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Annals of Neurology, 73(3), 370–380. https://doi.org/10.1002/ana.23794
4. Doppler, K., Appeltshauser, L., Villmann, C., et al. (2016). Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain, 139(10), 2617–2630. https://doi.org/10.1093/brain/aww189
5. Pascual-Goñi, E., Fehmi, J., Lleixà, C., et al. (2021). Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 144(4), 1183–1196. https://doi.org/10.1093/brain/awab014
6. Devaux, J. J., Miura, Y., Fukami, Y., et al. (2016). Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology, 86(9), 800–807. https://doi.org/10.1212/WNL.0000000000002418
7. Martín-Aguilar, L., Lleixà, C., Pascual-Goñi, E., et al. (2021). Clinical and laboratory features in anti-NF155 autoimmune nodopathy. Neurology: Neuroimmunology & Neuroinflammation, 9, e1098. https://doi.org/10.1212/NXI.0000000000001098
8. Appeltshauser, L., Junghof, H., Messinger, J., et al. (2023). Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage. Brain, 146(5), 1932–1949. https://doi.org/10.1093/brain/awac418
9. Delmont, E., Manso, C., Querol, L., et al. (2017). Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain, 140(7), 1851–1858. https://doi.org/10.1093/brain/awx124
10. Querol, L., Devaux, J., Rojas-Garcia, R., & Illa, I. (2017). Autoantibodies in chronic inflammatory neuropathies: Diagnostic and therapeutic implications. Nature Reviews Neurology, 13(9), 533–547. https://doi.org/10.1038/nrneurol.2017.84
11. Van den Bergh, P. Y. K., van Doorn, P. A., Hadden, R. D. M., et al. (2021). European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force—Second revision. Journal of the Peripheral Nervous System, 26(3), 242–268. https://doi.org/10.1111/jns.12455
12. Boyle, M. E., Berglund, E. O., Murai, K. K., et al. (2001). Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron, 30(2), 385–397. https://doi.org/10.1016/S0896-6273(01)00296-3
13. Salzer, J. L., Brophy, P. J., & Peles, E. (2008). Molecular domains of myelinated axons in the peripheral nervous system. Glia, 56(14), 1532–1540.
14. Miura, Y., Devaux, J. J., Fukami, Y., et al. (2015). Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain, 138(6), 1484–1491. https://doi.org/10.1093/brain/awv054
15. Dubey, D., Honorat, J. A., Shelly, S., et al. (2020). Contactin-1 autoimmunity: Serologic, neurologic, and pathologic correlates. Neurology: Neuroimmunology & Neuroinflammation, 7, e771. https://doi.org/10.1212/NXI.0000000000000771
16. Doppler, K., Appeltshauser, L., Wilhelmi, K., et al. (2015). Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. Journal of Neurology, Neurosurgery & Psychiatry, 86, 720–728. https://doi.org/10.1136/jnnp-2014-309916
17. Fehmi, J., Davies, A. J., Antonelou, M., et al. (2023). Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis. PLOS ONE, 18, e0281156. https://doi.org/10.1371/journal.pone.0281156
18. Querol, L., Rojas-García, R., Diaz-Manera, J., et al. (2015). Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurology: Neuroimmunology & Neuroinflammation, 2, e149. https://doi.org/10.1212/NXI.0000000000000149
19. Kasner, S. E. (2006). Clinical interpretation and use of stroke scales. The Lancet Neurology, 5, 603–612. https://doi.org/10.1016/S1474-4422(06)70495-1
20. Allen, J. A., Merkies, I. S. J., & Lewis, R. A. (2020). Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care: A review of clinical and laboratory assessment measures. JAMA Neurology, 77, 1159–1166. https://doi.org/10.1001/jamaneurol.2020.0781
21. Martín-Aguilar, L., Camps-Renom, P., Lleixà, C., et al. (2020). Serum neurofilament light chain predicts long-term prognosis in Guillain–Barré syndrome patients. Journal of Neurology, Neurosurgery & Psychiatry, 5, 70–77. https://doi.org/10.1136/jnnp-2020-323899
22. Benkert, P., Meier, S., Schaedelin, S., et al. (2022). Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. The Lancet Neurology, 21, 246–257. https://doi.org/10.1016/S1474-4422(22)00009-6
23. Abdelhak, A., Petermeier, F., Benkert, P., et al. (2023). Serum neurofilament light chain reference database for individual application in paediatric care: A retrospective modelling and validation study. The Lancet Neurology, 22, 826–833. https://doi.org/10.1016/S1474-4422(23)00210-7
24. Wieske, L., Martín-Aguilar, L., Fehmi, J., et al. (2021). Serum Contactin-1 in CIDP: A cross-sectional study. Neurology: Neuroimmunology & Neuroinflammation, 8, e1040. https://doi.org/10.1212/NXI.0000000000001040
25. Xu, Q., Liu, S., Zhang, P., et al. (2021). Characteristics of anti-Contactin1 antibody-associated autoimmune nodopathies with concomitant membranous nephropathy. Frontiers in Immunology, 12, 759187. https://doi.org/10.3389/fimmu.2021.759187
26. Siles, A. M., Martínez-Hernández, E., Araque, J., et al. (2018). Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies. Annals of Clinical and Translational Neurology, 5, 559–569. https://doi.org/10.1002/acn3.554
27. De Simoni, D., Ricken, G., Winklehner, M., et al. (2020). Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy. Neurology: Neuroimmunology & Neuroinflammation, 7, e763. https://doi.org/10.1212/NXI.0000000000000763
28. Carrera-García, L., Natera-de Benito, D., Lleixà, C., et al. (2019). Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. Neurology: Neuroimmunology & Neuroinflammation, 6, e602. https://doi.org/10.1212/NXI.0000000000000602
29. Appeltshauser, L., Messinger, J., Starz, K., et al. (2022). Diabetes mellitus is a possible risk factor for nodo-paranodopathy with antiparanodal autoantibodies. Neurology: Neuroimmunology & Neuroinflammation, 9, e1163. https://doi.org/10.1212/NXI.0000000000001163
30. Van Doorn, P. A., Van den Bergh, P. Y. K., Hadden, R. D. M., et al. (2023). European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain–Barré syndrome. European Journal of Neurology, 30, 3646–3674. https://doi.org/10.1111/ene.16073
31. Hashimoto, Y., Ogata, H., Yamasaki, R., et al. (2018). Chronic inflammatory demyelinating polyneuropathy with concurrent membranous nephropathy: An anti-paranode and podocyte protein antibody study and literature survey. Frontiers in Neurology, 9, 997. https://doi.org/10.3389/fneur.2018.00997
32. Taieb, G., Le Quintrec, M., Pialot, A., et al. (2019). “Neuro-renal syndrome” related to anti-contactin-1 antibodies. Muscle & Nerve, 59, E19–E21. https://doi.org/10.1002/mus.26392
33. Delmont, E., Brodovitch, A., Kouton, L., et al. (2020). Antibodies against the node of Ranvier: A real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. Journal of Neurology, 267, 3664–3672. https://doi.org/10.1007/s00415-020-10041-z
34. Papantoniou, M., Tsatinas, K. V., Papageorgiou, E., et al. (2024). Corticosteroid responsive anti-contactin-1 antibody seropositive chronic inflammatory demyelinating polyneuropathy: Report of two cases. Acta Neurologica Belgica, 124, 1089–1091. https://doi.org/10.1007/s13760-023-02463-z
35. Hou, Y., Zhang, C., Yu, X., et al. (2022). Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody. Frontiers in Immunology, 13, 939062. https://doi.org/10.3389/fimmu.2022.939062
36. Marino, M., Basile, U., Spagni, G., et al. (2020). Long-lasting rituximab-induced reduction of specific-but not total-IgG4 in MuSK-positive myasthenia gravis. Frontiers in Immunology, 11, 613. https://doi.org/10.3389/fimmu.2020.00613
37. Joly, P., Mouquet, H., Roujeau, J. C., et al. (2007). A single cycle of rituximab for the treatment of severe pemphigus. New England Journal of Medicine, 357, 545–552. https://doi.org/10.1056/NEJMoa067752
38. Labasque, M., Hivert, B., Nogales-Gadea, G., et al. (2014). Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. Journal of Biological Chemistry, 289, 7907–7918. https://doi.org/10.1074/jbc.M113.528489
39. Koike, H., Kadoya, M., Kaida, K. I., et al. (2017). Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. Journal of Neurology, Neurosurgery & Psychiatry, 88, 465–473. https://doi.org/10.1136/jnnp-2016-314895
40. Taieb, G., Jentzer, A., Vegezzi, E., et al. (2023). Effect of monovalency on anti-contactin-1 IgG4. Frontiers in Immunology, 14, 1021513. https://doi.org/10.3389/fimmu.2023.1021513
41. van Tilburg, S. J., Teunissen, C. E., Maas, C. C. H. M., et al. (2024). Dynamics and prognostic value of serum neurofilament light chain in Guillain–Barré syndrome. EBioMedicine, 102, 105072. https://doi.org/10.1016/j.ebiom.2024.105072
42. Durbec, P., Gennarini, G., Goridis, C., & Rougon, G. (1992). A soluble form of the F3 neuronal cell adhesion molecule promotes neurite outgrowth. Journal of Cell Biology, 117, 877–887. https://doi.org/10.1083/jcb.117.4.877
43. van Lierop, Z. Y., Wieske, L., Koel-Simmelink, M. J., et al. (2022). Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. Multiple Sclerosis Journal, 28, 102–110. https://doi.org/10.1177/13524585211010097
44. van Lierop, Z. Y., Noteboom, S., Steenwijk, M. D., et al. (2022). Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 28, 2231–2242. https://doi.org/10.1177/13524585221118676